Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumor infiltrating lymphocytes and continuous infusion interleukin-2 aftermetastasectomy in 61 patients with melanoma, colorectal and renal carcinoma
Autore:
Fabbri, M; Ridolfi, R; Maltoni, R; Ridolfi, L; Riccobon, A; Flamini, E; De Paola, F; Verdecchia, GM; Amadori, D;
Indirizzi:
Morgagni Pierantoni Hosp, Dept Med Oncol, I-47100 Forli, Italy Morgagni Pierantoni Hosp Forli Italy I-47100 Oncol, I-47100 Forli, Italy Morgagni Pierantoni Hosp, Dept Gen Surg, I-47100 Forli, Italy Morgagni Pierantoni Hosp Forli Italy I-47100 Surg, I-47100 Forli, Italy Ist Oncol Romagnolo, Forli, Italy Ist Oncol Romagnolo Forli ItalyIst Oncol Romagnolo, Forli, Italy
Titolo Testata:
TUMORI
fascicolo: 1, volume: 86, anno: 2000,
pagine: 46 - 52
SICI:
0300-8916(200001/02)86:1<46:TILACI>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECEIVING ADOPTIVE IMMUNOTHERAPY; DOSE RECOMBINANT INTERLEUKIN-2; METASTATIC MELANOMA; MALIGNANT-MELANOMA; RANDOMIZED TRIAL; ADVANCED CANCER; THERAPY; CELLS;
Keywords:
adoptive immunotherapy; interleukin-2; tumor-infiltrating lymphocytes;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Ridolfi, R Morgagni Pierantoni Hosp, Dept Med Oncol, Viale Forlanini, I-47100 Forli, Italy Morgagni Pierantoni Hosp Viale Forlanini Forli Italy I-47100 y
Citazione:
M. Fabbri et al., "Tumor infiltrating lymphocytes and continuous infusion interleukin-2 aftermetastasectomy in 61 patients with melanoma, colorectal and renal carcinoma", TUMORI, 86(1), 2000, pp. 46-52

Abstract

Aims and background: Adoptive immunotherapy with tumor infiltrating lymphocyte (TIL) reinfusion plus continuous interleukin-2 (IL-2) infusion could represent an innovative way of treating immunogenic tumors. This study therefore recruited melanoma, colorectal and renal carcinoma patients whose metastases had been surgically removed. Study design: The treatment was initially given to 22 patients with advanced disease and more recently to 39 disease-free (DF) patients after radicalmetastasectomy. The latter group was selected in view of a theoretically better lymphocyte/tumor cell ratio and with the aim to improve disease-free and overall survival (DFS-OS) in very high risk patients. The starting IL-2dose was 12 MIU/day (West's schedule); doses were modulated on the bases of toxicity parameters. Even though patients received different total amounts of IL-2, all of them completed the treatment. Results: The treatment was offered to 22 advanced-stage cancer patients (12 melanomas, 9 colorectal carcinomas, 1 kidney carcinoma). Few and short stabilizations were observed with a median survival of 12 months (range, 3-29), Subsequently, another 39 patients were treated in an adjuvant setting after radical metastasectomy (18 melanomas, 19 colorectal carcinomas, 2 kidney cancers). Eleven out of 17 DF melanoma patients (64.7%) are still free ofdisease after a median of 37+ months (range, 5+ - 69+), In the group of DFcolorectal cancer patients eight (44.4%) are still DF after a median of 21 months (range, 7+ - 67+ months). One of the two patients with kidney cancer is still DF after 28+ months. Two patients (1 melanoma and 1 colorectal cancer) had just been treated and were therefore not evaluable. Severe toxicity occurred in three cases but was rapidly resolved. There was a great diversity in IL-2 doses administered; comparison of the total IL-2 dose administered between the patients who are still DF and those who progressed revealed no difference between the two groups of colorectal cancer patients, whereas meianoma patients who progressed received an average IL-2 dose of 6.5MIU/day versus 15.8 MIU/day in DF patients. No differences were observed In any of the groups between the number of TILs reinfused and clinical response. Conclusions: The study is still ongoing; it has been decided to focus on DF melanoma patients after radical metastasectomy, for whom the data seem tobe encouraging. Further endpoints of the study are the role of IL-2 dosagein the adjuvant setting, and the possibility to make correlations between biological parameters and clinical results.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 07:47:39